Figure 6.

In vivo CD8⁺ T cell depletion abrogates the therapeutic effects of rVSV-NDV treatment. (A) The experimental set-up of CD8⁺ T cell depletion in B16OVA tumor-bearing mice treated with oncolytic rVSV-NDV vectors in vivo. Mice (N = 5–6) received either CD8 depletion antibody or IgG isotype control in 100 µL PBS by intraperitoneal injection 6 days after tumor implantation. One day later, complete depletion was confirmed by flow cytometry, and mice received VSV-NDV (1 × 10⁷ TCID50) or PBS in a 50 µL volume by intratumoral injection on day 0, 3, 6, and 14. (B) Tumor growth was monitored daily. (C) Tumor weights on day 7 post-treatment start. Data points indicate values of individual replicates (and group means ± SD are presented as bars); * indicates p < 0.05 and ** indicates p < 0.01.